BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siegl C, König-schuster M, Nakowitsch S, Koller C, Graf P, Unger-manhart N, Schindlegger Y, Kirchoff N, Knecht C, Prieschl-grassauer E, Sipos W. Pharmacokinetics of topically applied tacrolimus dissolved in Marinosolv, a novel aqueous eye drop formulation. European Journal of Pharmaceutics and Biopharmaceutics 2019;134:88-95. [DOI: 10.1016/j.ejpb.2018.11.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Bielory L, Schoenberg D. Ocular allergy: update on clinical trials. Curr Opin Allergy Clin Immunol 2019;19:495-502. [PMID: 31465314 DOI: 10.1097/ACI.0000000000000564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 García-Otero X, Díaz-Tomé V, Varela-Fernández R, Martín-Pastor M, González-Barcia M, Blanco-Méndez J, Mondelo-García C, Bermudez MA, Gonzalez F, Aguiar P, Fernández-Ferreiro A, Otero-Espinar FJ. Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop. Pharmaceutics 2021;13:149. [PMID: 33498753 DOI: 10.3390/pharmaceutics13020149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Prajapati M, Eiriksson FF, Loftsson T. Stability characterization, kinetics and mechanism of tacrolimus degradation in cyclodextrin solutions. Int J Pharm 2020;586:119579. [PMID: 32599134 DOI: 10.1016/j.ijpharm.2020.119579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mahmoudi A, Malaekeh-Nikouei B, Hanafi-Bojd MY, Toloei M, Hosseini M, Nikandish M. Preliminary In Vivo Safety Evaluation of a Tacrolimus Eye Drop Formulation Using Hydroxypropyl Beta Cyclodextrin After Ocular Administration in NZW Rabbits. Clin Ophthalmol 2020;14:947-53. [PMID: 32273679 DOI: 10.2147/OPTH.S229405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Modi D, Mohammad, Warsi MH, Garg V, Bhatia M, Kesharwani P, Jain GK. Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ tacrolimus gel. J Biomater Sci Polym Ed 2021;:1-25. [PMID: 34013840 DOI: 10.1080/09205063.2021.1932359] [Reference Citation Analysis]
6 Liu YC, Lin MT, Ng AHC, Wong TT, Mehta JS. Nanotechnology for the Treatment of Allergic Conjunctival Diseases. Pharmaceuticals (Basel) 2020;13:E351. [PMID: 33138064 DOI: 10.3390/ph13110351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Nayak K, Misra M. PEGylated microemulsion for dexamethasone delivery to posterior segment of eye. J Biomater Sci Polym Ed 2020;31:1071-90. [PMID: 32149562 DOI: 10.1080/09205063.2020.1740964] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nakowitsch S, Koller C, Seifert JM, König-Schuster M, Unger-Manhart N, Siegl C, Kirchoff N, Foglar E, Graf C, Morokutti-Kurz M, Neurath M, Sladek S, Knecht C, Sipos W, Prieschl-Grassauer E, Grassauer A. Saponin Micelles Lead to High Mucosal Permeation and In Vivo Efficacy of Solubilized Budesonide. Pharmaceutics 2020;12:E847. [PMID: 32899549 DOI: 10.3390/pharmaceutics12090847] [Reference Citation Analysis]
9 García-Otero X, Mondelo-García C, González F, Perez-Fernandez R, Avila L, Antúnez-López JR, González-Barcia M, Adan A, Aguiar P, Otero-Espinar FJ, Bermúdez MA, Fernández-Ferreiro A. Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model. Pharmaceutics 2021;13:1737. [PMID: 34684030 DOI: 10.3390/pharmaceutics13101737] [Reference Citation Analysis]
10 Badr MY, Abdulrahman NS, Schatzlein AG, Uchegbu IF. A polymeric aqueous tacrolimus formulation for topical ocular delivery. International Journal of Pharmaceutics 2021;599:120364. [DOI: 10.1016/j.ijpharm.2021.120364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang X, Muddana S, Kumar SR, Burton JN, Labroo P, Shea J, Stocking P, Siegl C, Archer B, Agarwal J, Ambati BK. Topical Pergolide Enhance Corneal Nerve Regrowth Following Induced Corneal Abrasion. Invest Ophthalmol Vis Sci 2020;61:4. [PMID: 31999819 DOI: 10.1167/iovs.61.1.4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Maulvi FA, Shetty KH, Desai DT, Shah DO, Willcox MDP. Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration. Int J Pharm 2021;608:121105. [PMID: 34537269 DOI: 10.1016/j.ijpharm.2021.121105] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Rebibo L, Tam C, Sun Y, Shoshani E, Badihi A, Nassar T, Benita S. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. J Control Release 2021;333:283-97. [PMID: 33798665 DOI: 10.1016/j.jconrel.2021.03.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]